Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Acquisition and Product Sale Growth Drives Amgen's Q4 Profit Up 30%

Biopharmaceutical juggernaut Amgen (NASDAQ: AMGN  ) demonstrated to investors that its years of middling growth could be in the rearview mirror with the release of its fourth-quarter earnings results after the closing bell.

For the quarter, Amgen saw total revenue increase 13% to $5.01 billion as product sales jumped 11% to $4.8 billion and profit increased 30% to $1.82 per share from $1.40 in the year-ago period.

With the exception of Neupogen, whose sales fell 1%, and anemia drug Aranesp which saw a 4% sales decline, every other drug in Amgen's product portfolio delivered positive growth. Most notably, Neulasta saw total revenue rose by 10% to $1.1 billion while rheumatoid arthritis drug Enbrel, its top-selling drug, witnessed a 3% increase in revenue to $1.2 billion thanks to higher pricing and the end of a collaborative pact with Pfizer (NYSE: PFE  ) that had previously resulted in a profit share between the two companies.

Other highlights include osteoporosis combo Xgeva and Prolia, which saw combined sales rise 41% to $522 million, and multiple myeloma drug Kyprolis, which it acquired when it purchased Onyx Pharmaceuticals. Kyrpolis sales totaled $73 million during the quarter.

Costs did shoot higher during the quarter, but this was largely to be expected with the addition of Onyx Pharmaceuticals' pipeline to Amgen's portfolio. Research and development expenses rose 27% to $1.17 billion, primarily to support its late-stage clinical programs, as selling and administrative expenses declined modestly.

Looking ahead, Amgen is forecasting 2014 full-year revenue of $19.2 billion to $19.6 billion -- representing sales growth of 4% year over year at the midpoint -- and EPS of $7.90 to $8.20, which would represent 21% year-on-year growth at the midpoint.

Shares of Amgen were down fractionally in after-hours trading. 

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2813780, ~/Articles/ArticleHandler.aspx, 8/31/2015 4:02:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,572.89 -70.12 -0.42%
S&P 500 1,975.53 -13.34 -0.67%
NASD 4,785.90 -42.43 -0.88%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 3:46 PM
AMGN $152.79 Down -3.10 -1.99%
Amgen, Inc. CAPS Rating: ****